GlassScriptPhysician profile
Tamis M Bright
NPI 1871533372
$6,492.11
in general payments reported to CMS, 2019-2025
26 companies · $1,104 in 2025
The $1,104 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,732 · 2020: $155 · 2021: $724 · 2022: $716 · 2023: $1,054 · 2024: $1,006 · 2025: $1,104.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,120 · Education: $44.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,120.17 |
| Education | $44.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,581.48 | 2019-2025 | Ozempic, Rybelsus |
| Amgen INC. | $1,015.89 | 2019-2025 | Evenity, Tepezza, Prolia |
| Inspire Medical Systems, INC. | $513.19 | 2022-2023 | Inspire |
| Lilly USA, LLC | $379.93 | 2019-2024 | Mounjaro, Humulin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $310.65 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $283.33 | 2024-2025 | |
| Horizon Therapeutics Plc | $248.95 | 2022-2023 | Tepezza |
| Insulet Corporation | $235.28 | 2021-2025 | Omnipod |
| Medtronic, INC. | $230.70 | 2024-2025 | Minimed 780g |
| Abbvie INC. | $216.48 | 2019 | |
| Sanofi-Aventis U.S. LLC | $197.34 | 2019-2024 | |
| Regeneron Pharmaceuticals, INC. | $176.64 | 2019-2021 | |
| Enterra Medical, INC. | $160.04 | 2025 | |
| Xeris Pharmaceuticals, INC. | $151.78 | 2021-2024 | Recorlev |
| Neurocrine Biosciences, INC. | $139.29 | 2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $120.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $116.57 | 2022-2025 | Entyvio, Gattex |
| Abbott Laboratories | $108.76 | 2021-2025 | Freestyle Libre 3 |
| Shire North American Group INC | $89.80 | 2019 | |
| Tandem Diabetes Care, INC. | $52.76 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Ardelyx, INC. | $43.37 | 2023-2025 | Ibsrela |
| Ascendis Pharma Endocrinology INC | $36.88 | 2025 | Yorvipath |
| Janssen Biotech, INC. | $31.68 | 2024 | Stelara, Tremfya |
| Radius Health, INC. | $23.26 | 2025 | Tymlos |
| Ipsen Biopharmaceuticals, INC | $16.06 | 2025 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $12.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamis Bright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.